Life Sciences

Seventure’s Health for Life Capital II™ fund qualifies for French government’s financing initiative (“TIBI”) as first and only fund in the microbiome field
30 July 2020

Seventure’s Health for Life Capital II™ fund qualifies for French government’s financing initiative (“TIBI”) as first and only fund in the microbiome field

Seventure Partners, a European leader in financing innovation, announces today that the technical committee of the French government initiative, which was set up to support...

Read the press release
Enterome initiates first clinical trial with EO2401 – an innovative microbiomeantigen based cancer immunotherapy candidate targeting aggressive brain cancer
30 July 2020

Enterome initiates first clinical trial with EO2401 – an innovative microbiomeantigen based cancer immunotherapy candidate targeting aggressive brain cancer

ENTEROME SA, a clinical-stage biopharmaceutical company leveraging its unique knowledge of the microbiome-immunoinflammation axis to develop next-generation therapeutics,...

Read the press release
Citryll completes € 18.5 M fundraise to develop CIT-013, an antibody targeting Neutrophil Extracellular Traps
2 July 2020

Citryll completes € 18.5 M fundraise to develop CIT-013, an antibody targeting Neutrophil Extracellular Traps

OSS, Netherlands-Citryll announced it closed a total fundraise of € 18.5 million, led by Seventure (including their Health for Life Capital II fund), co-led by BioGeneration...

Read more
CARB-X FUNDS ELIGO BIOSCIENCE TO DEVELOP CRISPR-BASED THERAPEUTICS DERIVED FROM BACTERIOPHAGES TO KILL SUPERBUGS AND PREVENT DEADLY INFECTIONS IN TRANSPLANT PATIENTS
2 July 2020

CARB-X FUNDS ELIGO BIOSCIENCE TO DEVELOP CRISPR-BASED THERAPEUTICS DERIVED FROM BACTERIOPHAGES TO KILL SUPERBUGS AND PREVENT DEADLY INFECTIONS IN TRANSPLANT PATIENTS

(BOSTON) – CARB-X announced today that it is awarding up to US$1.82 million to Eligo Bioscience in Paris, France, with additional funding for a total award of up to US$7.05...

Read more
Enterome completes €46.3 million ($52.6 million) financing to progress the clinical development of its therapeutic pipeline
25 June 2020

Enterome completes €46.3 million ($52.6 million) financing to progress the clinical development of its therapeutic pipeline

ENTEROME SA, a clinical-stage biopharmaceutical company leveraging its unique knowledge of the microbiome-immunoinflammation axis to develop next-generation therapeutics, today...

Read the press release
Axial Biotherapeutics Announces Positive Topline Results from Phase 1b/2a Clinical Trial of AB-2004 for the Treatment of Autism Spectrum Disorder
3 April 2020

Axial Biotherapeutics Announces Positive Topline Results from Phase 1b/2a Clinical Trial of AB-2004 for the Treatment of Autism Spectrum Disorder

Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders,...

Read the press release
MaaT Pharma Announces €18 Million Series B Financing Round to Support Further Clinical Development of Microbiome Biotherapeutics
6 February 2020

MaaT Pharma Announces €18 Million Series B Financing Round to Support Further Clinical Development of Microbiome Biotherapeutics

MaaT Pharma announced today an €18 million Series B financing round including a microbiome-focused US investor, SymBiosis, LLC, and support from its existing investors...

Read more
C-section babies are missing key microbes via nature.com
20 September 2019

C-section babies are missing key microbes via nature.com

How a baby is born has a profound impact on their microbiome — the community of microbes that colonize the body. That’s the finding of the largest ever study of the newborn...

Read more
LiMM Therapeutics incorporated to translate breakthrough science into first in class therapeutic agents
25 June 2019

LiMM Therapeutics incorporated to translate breakthrough science into first in class therapeutic agents

LiMM Therapeutics was created to lead development of a new class of therapeutic agents - neuronal reprogrammers of innate lymphocytes. The company is based on pioneering...

Read the press release
Vedanta Biosciences Closes Extended $45.5 Million Series C Financing
13 May 2019

Vedanta Biosciences Closes Extended $45.5 Million Series C Financing

Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human...

Read more

By continuing your browsing on this site, you accept the use of cookies to carry out statistics of anonymous visits. Read more

Authorize Refuse